Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.60 |
| ▸ | CCR3 | P51677 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 3/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4784273 | 1.00 | LTA4H (0.61) | LTA4HACHECCR3SLC6A3SIGMAR1 | |
| SCHEMBL4222408 | 1.00 | LTA4H (0.61) | LTA4HACHECCR3SLC6A3SIGMAR1 | |
| SCHEMBL25285380 | 0.90 | SLC6A3 (0.61) | LTA4HACHECCR3SLC6A3SIGMAR1 | |
| SCHEMBL21197752 | 0.90 | SLC6A3 (0.61) | LTA4HACHECCR3SLC6A3SIGMAR1 | |
| SCHEMBL1803484 | 0.89 | ACHE (0.69) | ACHECCR3SLC6A3SIGMAR1HTR2A | |
| Hydrochloric Acid SCHEMBL8788285 | 0.88 | ACHE (0.67) | ACHECCR3SLC6A3SIGMAR1HTR2A | |
| Hydrochloric Acid SCHEMBL11534786 | 0.88 | ACHE (0.67) | ACHECCR3SLC6A3SIGMAR1HTR2A | |
| SCHEMBL4322160 | 0.84 | ACHE (0.54) | ACHECCR3SLC6A3SIGMAR1HTR2A | |
| SCHEMBL4322172 | 0.84 | ACHE (0.54) | ACHECCR3SLC6A3SIGMAR1HTR2A | |
| SCHEMBL4322177 | 0.84 | ACHE (0.54) | ACHECCR3SLC6A3SIGMAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107567445-B | 2-phenyl-3H-imidazo [4,5-B ] pyridine derivatives useful as inhibitors of mammalian tyrosine kinase ROR1 activity | 坎塞拉有限公司 | 2021-06-29 | — | — | CN | disclosed |
| EP-1796678-B1 | CARBOXAMIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-04-14 | — | — | EP | disclosed |
| US-7390798-B2 | Carboxamide spirolactam CGRP receptor antagonists | MERCK & CO., INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390798-B2 | Carboxamide spirolactam CGRP receptor antagonists | MERCK & CO., INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-20070293470-A1 | Carboxamide Spirolactam Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070293470-A1 | Carboxamide Spirolactam Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2007-12-20 | — | — | US | disclosed |
| US-6468998-B1 | ANTAGONIZE SEROTONIN 2 RECEPTORS, SUPPRESS PLATELET AGGREGATION, IMPROVE PERIPHERAL CIRCULATION AND PROMOTE LACHRYMATION | MITSUBISHI PHARMA CORPORATION (JP) | 2002-10-22 | — | — | US | disclosed |
| EP-1125922-A1 | PYRROLIDINE COMPOUNDS AND MEDICINAL UTILIZATION THEREOF | Welfide Corporation (JP) | 2001-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293470-A1 | Carboxamide Spirolactam Cgrp Receptor Antagonists | BDKRB1, CALCRL, BDKRB2 | LTA4H 1376/4885ACHE 1465/4885CCR3 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.